Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Tours Cedex, France Clinical Trials

A listing of Tours Cedex, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

Triptorelin Flutamide and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer

OBJECTIVES: - Compare the impact of neoadjuvant androgen blockade therapy comprising triptorelin and flutamide followed by conformal external beam radiotherapy and continued androgen blockage therapy vs conformal external beam radiotherapy alone in patients with stage II or III prostate cancer. - Compare the survival rate, in terms of 5-year clinical ...

Phase

0.0 miles

Learn More »

Detection of Chlamydia Trachomatis Neisseria Gonorrhoeae and Mycoplasma Genitalium by Real-time Multiplex Polymerase Chain Reaction (PCR) After Pooling Pharyngeal Anorectal and Urinary Samples

Patients detected positive for one of the three (Sexually Transmitted Infection)STIs (Chlamydia trachomatis, Neisseria gonorrhoeae or Mycoplasma genitalium) on one site will be re-sampled twice at each of the three sites (pharynx, rectum, urine) before receiving antibiotics. Then, a real-time multiplex PCR will be performed on the pooled sample (merging ...

Phase N/A

0.0 miles

Learn More »

Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy

The TEMPOS-GEniToUrinary Group (GETUG) study is a multicenter, randomized-controlled medico-economic study comparing brachytherapy to SBRT in low and intermediate risk prostate cancer, particularly focused on the issue of erectile dysfunction. A total of 240 potent patients are randomized in two arms. The experimental arm consists of SBRT delivering 7.25 Gy ...

Phase

0.0 miles

Learn More »

A Study of Apalutamide in Participants With High Risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

High-risk prostate cancer accounts for approximately 15 percent (%) of newly diagnosed prostate cancers. A systemic therapy that eradicates micrometastatic disease is needed to improve survival in high-risk participants undergoing radical prostatectomy. It is hypothesized that androgen blockade prior to and after radical prostatectomy may improve outcomes for participants at ...

Phase

0.79 miles

Learn More »